| General Information | |
|---|---|
| ZINC ID | ZINC000096938361 |
| Molecular Weight (Da) | 349 |
| SMILES | CCCCCn1c2ccccc2c2cc(C(=O)N3CCCCC3)ncc21 |
| Molecular Formula | C22N3O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 102.461 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 26 |
| LogP | 4.833 |
| Activity (Ki) in nM | 35.481 |
| Polar Surface Area (PSA) | 38.13 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.95816308 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 13 |
| Fraction csp3 | 0.45 |
| Ilogp | 3.51 |
| Xlogp3 | 4.63 |
| Wlogp | 4.63 |
| Mlogp | 3.19 |
| Silicos-it log p | 4.4 |
| Consensus log p | 4.07 |
| Esol log s | -4.9 |
| Esol solubility (mg/ml) | 0.00442 |
| Esol solubility (mol/l) | 0.0000127 |
| Esol class | Moderately |
| Ali log s | -5.16 |
| Ali solubility (mg/ml) | 0.00244 |
| Ali solubility (mol/l) | 0.00000697 |
| Ali class | Moderately |
| Silicos-it logsw | -6.4 |
| Silicos-it solubility (mg/ml) | 0.000139 |
| Silicos-it solubility (mol/l) | 0.00000039 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.14 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 2.66 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.217 |
| Logd | 3.994 |
| Logp | 5.155 |
| F (20%) | 0.402 |
| F (30%) | 0.161 |
| Mdck | 1.33E-05 |
| Ppb | 0.9431 |
| Vdss | 1.872 |
| Fu | 0.0325 |
| Cyp1a2-inh | 0.746 |
| Cyp1a2-sub | 0.504 |
| Cyp2c19-inh | 0.809 |
| Cyp2c19-sub | 0.091 |
| Cl | 4.529 |
| T12 | 0.053 |
| H-ht | 0.887 |
| Dili | 0.896 |
| Roa | 0.357 |
| Fdamdd | 0.893 |
| Skinsen | 0.141 |
| Ec | 0.003 |
| Ei | 0.046 |
| Respiratory | 0.863 |
| Bcf | 1.594 |
| Igc50 | 4.814 |
| Lc50 | 5.426 |
| Lc50dm | 4.943 |
| Nr-ar | 0.128 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.702 |
| Nr-aromatase | 0.899 |
| Nr-er | 0.205 |
| Nr-er-lbd | 0.009 |
| Nr-ppar-gamma | 0.013 |
| Sr-are | 0.604 |
| Sr-atad5 | 0.048 |
| Sr-hse | 0.705 |
| Sr-mmp | 0.346 |
| Sr-p53 | 0.617 |
| Vol | 378.168 |
| Dense | 0.923 |
| Flex | 0.273 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 3 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.608 |
| Synth | 2.186 |
| Fsp3 | 0.455 |
| Mce-18 | 46.25 |
| Natural product-likeness | -1 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |